JP2023543896A5 - - Google Patents
Info
- Publication number
- JP2023543896A5 JP2023543896A5 JP2023520021A JP2023520021A JP2023543896A5 JP 2023543896 A5 JP2023543896 A5 JP 2023543896A5 JP 2023520021 A JP2023520021 A JP 2023520021A JP 2023520021 A JP2023520021 A JP 2023520021A JP 2023543896 A5 JP2023543896 A5 JP 2023543896A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085612P | 2020-09-30 | 2020-09-30 | |
| US63/085,612 | 2020-09-30 | ||
| PCT/US2021/052819 WO2022072601A1 (en) | 2020-09-30 | 2021-09-30 | ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543896A JP2023543896A (ja) | 2023-10-18 |
| JP2023543896A5 true JP2023543896A5 (https=) | 2024-10-08 |
Family
ID=80951827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520021A Pending JP2023543896A (ja) | 2020-09-30 | 2021-09-30 | 抗アデノシン受容体（Ａ２ａＲ）抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230340132A1 (https=) |
| EP (1) | EP4222173A4 (https=) |
| JP (1) | JP2023543896A (https=) |
| CN (1) | CN116348140A (https=) |
| AU (1) | AU2021351500A1 (https=) |
| CA (1) | CA3194285A1 (https=) |
| WO (1) | WO2022072601A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| CN116333127B (zh) * | 2022-06-28 | 2026-03-24 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN119303103A (zh) * | 2023-07-11 | 2025-01-14 | 清华大学 | 一种抗体偶联物及其应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025257365A1 (en) | 2024-06-14 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Adenosine a2a antagonists for the treatment of endometriosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| JP2011097869A (ja) * | 2009-11-05 | 2011-05-19 | Japan Science & Technology Agency | 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体 |
| WO2013040358A2 (en) * | 2011-09-14 | 2013-03-21 | University Of Washington Through Its Center For Commercialization | Assays and compositions for detection of agr2 |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US20140322236A1 (en) * | 2013-03-15 | 2014-10-30 | Sdix, Llc | Anti-human adora2a antibodies |
| DK3515478T3 (da) * | 2016-09-21 | 2024-05-21 | Nextcure Inc | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf |
| WO2020185739A1 (en) * | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
-
2021
- 2021-09-30 US US18/028,917 patent/US20230340132A1/en active Pending
- 2021-09-30 CA CA3194285A patent/CA3194285A1/en active Pending
- 2021-09-30 WO PCT/US2021/052819 patent/WO2022072601A1/en not_active Ceased
- 2021-09-30 JP JP2023520021A patent/JP2023543896A/ja active Pending
- 2021-09-30 EP EP21876458.7A patent/EP4222173A4/en active Pending
- 2021-09-30 AU AU2021351500A patent/AU2021351500A1/en active Pending
- 2021-09-30 CN CN202180067415.9A patent/CN116348140A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12258411B2 (en) | Anti-CCR8 antibodies and uses thereof | |
| JP7844558B2 (ja) | リンパ球における阻害経路の中和 | |
| JP2023543896A5 (https=) | ||
| JP6955507B2 (ja) | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 | |
| AU2021201451A1 (en) | Proteins binding NKG2D, CD16, and EGFR, CCR4, or PD-L1 | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2022502052A5 (https=) | ||
| JP2019001789A (ja) | ヒトｃｓｆ−１ｒに対する抗体とヒトｐｄ−ｌ１に対する抗体の併用療法 | |
| JP2022507295A5 (https=) | ||
| JP2020514363A5 (https=) | ||
| KR20200038530A (ko) | Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질 | |
| JP2018533371A5 (https=) | ||
| JP2022044795A (ja) | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2020502147A5 (https=) | ||
| KR20190120770A (ko) | Psma, nkg2d 및 cd16에 결합하는 단백질 | |
| JP2021520201A5 (https=) | ||
| US20240262913A1 (en) | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies | |
| WO2021092060A1 (en) | Methods of treatment | |
| JP2024097985A (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| US20240124607A1 (en) | Proteins binding nkg2d, cd16, and ceacam5 | |
| KR20240099371A (ko) | 암 치료 및 gprc5dxcd3 이중특이성 항체의 효능을 향상시키는 방법 | |
| TH2101001840A (th) | แอนติบอดีสารต้าน hla-g, องค์ประกอบซึ่งประกอบรวมด้วยแอนติบอดีสารต้าน hla-g และวิธีของการใช้แอนติบอดีสารต้าน hla-g | |
| EA047743B1 (ru) | Антитела к gitr и варианты их применения |